Mayne Pharma Group Limited
PublicMayne Pharma Group Limited is now publicly traded
The data on this page reflects Mayne Pharma Group Limited's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Seed
Nov 28, 2023
Est. Valuation at Exit
$50M
Total Funding Raised
$5M
Company Overview
Mayne Pharma Group Limited is an Australian publicly traded (ASX:MYX) specialty pharmaceutical company. The company's primary business involves the development, manufacturing, and commercialization of novel branded and generic pharmaceutical products. It has a particular focus on the therapeutic areas of women's health and dermatology. In addition to its own product lines, Mayne Pharma provides contract development and manufacturing organization (CDMO) services to other pharmaceutical companies from its facilities in Australia and the United States. The company has a history spanning over 40 years in developing oral drug delivery systems and markets its products globally.
AI Layer
Non-AI
Keywords
Mayne Pharma Group Limited Comparables
Compare Mayne Pharma Group Limited with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Millicent Pharma | 68% | |
| Leading Pharma | 58% | |
| Evestra, Inc. | 51% | |
Mayne Pharma Group Limited Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Nov 28, 2023 |
Key People
Founding team and executive leadership
Mayne Pharma Group Limited Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GSR Markets | Seed |
| Alti5 | Seed |
| Cypher Capital | Seed |
| Foresight Ventures | Seed |
| Bing Ventures | Seed |
| Redpoint China Ventures | Seed |
| Hack VC | Seed |
Mayne Pharma Group Limited Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
